Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Trial details
- Registry ID
- NCT03878849
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as E7449, MGI25036
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian CancerNCT03878849 | Allarity Therapeutics | Phase 2 | Recruiting | 2027-03Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |